1. Stocks
    2. /
  2. Imugene Limited (ASX: IMU)
    3. /

Imugene Limited (ASX: IMU) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Imugene Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

    • Imugene Limited (ASX: IMU)
    Latest News

    Ordinary Australians waiting at the bus stop using their phones to trade ASX 200 shares today
    Share Gainers

    Here are the top 10 ASX 200 shares today

    | Brooke Cooper

    Guess which ASX 200 lithium stock led the index on Friday.

    Read more »

    A women throws her paperwork in the air with a wry smile on her face.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    | Brooke Cooper

    Guess which ASX 200 tech stock outperformed all others on the index on Friday.

    Read more »

    Top ten gold trophy.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    | Brooke Cooper

    Guess which ASX 200 coal stock posted a near 9% gain today.

    Read more »

    Share Gainers

    Here are the top 10 ASX 200 shares today

    | Brooke Cooper

    Guess which insurance giant outperformed all other ASX 200 stocks today.

    Read more »

    A couple working on a laptop laugh as they discuss their ASX share portfolio.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    | Brooke Cooper

    Guess which ASX 200 healthcare share defied the market's downturn on Friday.

    Read more »

    Smiling man sits in front of a graph on computer while using his mobile phone.
    Share Gainers

    Why Appen, Endeavour, Imugene, and Treasury Wine shares are pushing higher

    | James Mickleboro

    These ASX shares are defying market weakness and ending the week with a bang...

    Read more »

    Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
    Healthcare Shares

    Guess which ASX 200 healthcare share is surging 5% on a new US patent?

    | Brooke Cooper

    The company has announced a "particularly important" intellectual property win.

    Read more »

    A woman with a broad smile on her face holds up ten fingers.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    | Brooke Cooper

    These ASX 200 shares outperformed on the back of earnings today.

    Read more »

    A woman with a broad smile on her face holds up ten fingers.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    | Brooke Cooper

    Guess which ASX 200 travel stock bested the rest on Wednesday.

    Read more »

    A man and a woman sit in front of a laptop looking fascinated and captivated.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    | Brooke Cooper

    Guess which ASX 200 healthcare stock outperformed all others after the company posted earnings today.

    Read more »

    A casually dressed woman at home on her couch looks at index fund charts on her laptop
    Share Gainers

    Here are the top 10 ASX 200 shares today

    | Brooke Cooper

    As lithium and iron ore stocks suffered, these ASX 200 shares rocketed higher.

    Read more »

    Top ten gold trophy.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    | Brooke Cooper

    Guess which ASX 200 lithium share outperformed all others on Thursday.

    Read more »

    Frequently Asked Questions

    Imugene does not pay dividends at this stage. 

    Imugene Ltd (ASX: IMU) listed on the ASX on 24 November 1993.

    IMU ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Imugene Limited

    Imugene Ltd (ASX: IMU) is a biotechnology company working in cancer immunotherapy.

    The company specialises in clinical-stage immuno-oncology therapies. Its product pipeline includes Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard-care drugs and immunotherapies.

    The company's lead product is HER-Vaxx, a proprietary cancer vaccine for the treatment of gastric and breast cancer, where the cancer is HER-2 positive. The vaccine has demonstrated it stimulates a polyclonal antibody response to HER2/neu. 

    Imugene's various immunotherapy products are involved in ongoing clinical trials involving cancer specialists and researchers worldwide.

    Profile

    since

    Note